ClinicalTrials.gg
RecruitingNCT06566586Updated Nov 20, 2024

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

A Phase 2 interventional study of TQB3702 tablets+Chemotherapy regimen in B-cell Lymphoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
58th of 273
80 · median 30
Started
2024
with 27 others
Phase 2
51 of 283
23 open now
Primary completion
2026-03
later than 41 of 145 live
Registered
205th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 58th largest by planned enrollment of the 273 interventional ones that give a count, is one of 28 that started in 2024, is one of 51 in phase 2, reaches primary completion later than 41 of the 145 other live ones, and was the 205th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma

03

Conditions studied

  • B-cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study, signed the , and the compliance was good;
  • Age: 18 years old ≤ age (when signing the informed consent) ≤75 years old; (ECOG) score: 0-2; Expected survival of more than 3 months;
  • confirmed B-cell lymphomas of the following types that meet the 2022 World Health Organization (WHO) diagnostic criteria:

    1. indolent B-cell lymphoma
    2. Diffuse large B cell lymphoma(DLBCL)
  • Previous treatment: Relapsed/refractory inert B-cell lymphoma: have received at least one previous line of systemic standard therapy
  • Have at least one .
  • The main organs function well.
  • Female subjects of reproductive age should agree to use (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the end of the study; Have a negative serum pregnancy test within 7 days prior to study enrollment and must be a non-lactating subject; Male subjects should agree to use avoidance during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Have had or are currently suffering from other malignant tumors within 3 years prior to the first medication.
  • Known or suspected central nervous system (CNS) aggression.
  • inert B-cell lymphoma: previous hematopoietic stem cell transplantation, or autologous hematopoietic stem cell transplantation within 3 months before the first treatment;
  • Recurrent/refractory indolent B-cell lymphoma: toxic reactions that do not return to ≤ National Cancer Institute standard for common toxic reactions (NCI-CTC) AE Grade 1 due to any previous treatment, excluding hair loss and fatigue;
  • Have multiple factors that affect oral drug absorption (such as inability to swallow, chronic diarrhea, and intestinal obstruction);
  • Received major surgical treatment or significant traumatic injury within 28 days before the start of study treatment;
  • Hyperkinetic/venous thrombosis events occurred within 6 months before the first medication;
  • Have a history of psychotropic drug abuse and can not quit or have mental disorders;
  • Subjects with any severe and/or uncontrolled disease;
  • Received or messenger ribonucleic acid (mRNA) vaccine within 4 weeks before the first dose, or planned to receive live vaccine or mRNA vaccine during the study;
  • Participated in clinical trials of other antitumor drugs within 4 weeks before the first medication;
  • Subjects who, in the judgment of the investigator, have concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are not suitable for enrollment for other reasons.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    TQB3702 tablets+Chemotherapy regimen

    TQB3702 tablets 200mg, every 4 weeks for a treatment cycle. Chemotherapy regimen:Every 3 or 4 weeks is a treatment cycle, with 6 or 12 cycles of combination therapy

    Drug: TQB3702 tablets+Chemotherapy regimen

Interventions

  • DrugTQB3702 tablets+Chemotherapy regimen

    TQB3702 tablets: Tyrosine kinase inhibitor; Chemotherapy regimen:inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis;

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.

    Time frame: Up to 2 years

  2. Complete response rate (CRR)

    The rate of complete tumor remission

    Time frame: Up to 2 years

Secondary outcomes

  1. Adverse events (AE) and serious adverse events (SAE)

    Incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators

    Time frame: Baseline to up to 28 days

  2. ORR and CRR at the end of combination therapy

    Objective response rate and complete remission rate at the end of combination therapy.

    Time frame: Up to 1 year

  3. Progression-free survival (PFS)

    PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.

    Time frame: Up to 2 years

  4. Duration of response (DOR)

    The period from the participants first achieving CR or PR to disease progression

    Time frame: Up to 2 years

  5. Overall survival (OS)

    OS is defined as the time from the first administration to all-cause death

    Time frame: Up to all-cause death

  6. 1-year PFS and OS

    1-year Progression-free survival and Overall survival rates

    Time frame: Up to 1 year

  7. 2-years PFS and OS

    2-years Progression-free survival and Overall survival rates

    Time frame: Up to 2 years

07

Study locations

1 of 30 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2026, 16 months after the start.

Of 121 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 73. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 22, 2024
StartActual
Nov 6, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Dec 2027
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06566586
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Nov 6, 2024
Primary completion
Mar 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2024

Study contacts

Zengjun Li, Doctor
Contact
zengjunli@163.com
13642138692
Fei Li, Doctor
Contact
yx021021@sina.com
13970038386

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion